Cargando…

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease

BACKGROUND: High‐sensitivity troponin (hs‐TNT), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry cardiomyopathy. We performed a prospective analysis of hs‐TNT as a biomarker for myocardial changes in Fabry patients and a retrospective longitudinal follow‐up study to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seydelmann, Nora, Liu, Dan, Krämer, Johannes, Drechsler, Christiane, Hu, Kai, Nordbeck, Peter, Schneider, Andreas, Störk, Stefan, Bijnens, Bart, Ertl, Georg, Wanner, Christoph, Weidemann, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937248/ https://www.ncbi.nlm.nih.gov/pubmed/27247331 http://dx.doi.org/10.1161/JAHA.115.002839

Ejemplares similares

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
por: Krämer, Johannes, et al.
Publicado: (2015)

Potential role of vitamin D deficiency on Fabry cardiomyopathy
por: Drechsler, Christiane, et al.
Publicado: (2013)

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
por: Liu, Dan, et al.
Publicado: (2018)

Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy
por: Liu, Dan, et al.
Publicado: (2016)

Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018)

Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles
por: Oder, Daniel, et al.
Publicado: (2016)

Value of the CHA(2)DS(2)-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
por: Liu, Dan, et al.
Publicado: (2018)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Publicado: (2016)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
por: Weidemann, F, et al.
Publicado: (2013)

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y
por: Oder, Daniel, et al.
Publicado: (2016)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease
por: Wagner, Martin, et al.
Publicado: (2014)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Value of tissue Doppler-derived Tei index and two-dimensional speckle tracking imaging derived longitudinal strain on predicting outcome of patients with light-chain cardiac amyloidosis
por: Liu, Dan, et al.
Publicado: (2017)

Predictive Value of Assessing Diastolic Strain Rate on Survival in Cardiac Amyloidosis Patients with Preserved Ejection Fraction
por: Liu, Dan, et al.
Publicado: (2014)

Characterization of vertigo and hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2018)

Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

Continuous Cardiac Troponin I Release in Fabry Disease
por: Feustel, Andreas, et al.
Publicado: (2014)

Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study
por: Üçeyler, Nurcan, et al.
Publicado: (2013)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study
por: Oder, Daniel, et al.
Publicado: (2018)

Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
por: Köping, Maria, et al.
Publicado: (2017)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Fibrosis: a key feature of Fabry disease with potential therapeutic implications
por: Weidemann, Frank, et al.
Publicado: (2013)

Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease
por: Kraus, Daniel, et al.
Publicado: (2018)

Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages
por: Gerhardt, Louisa M. S., et al.
Publicado: (2022)

Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020)

Late-Stage Fabry Disease With Advanced Cardiomyopathy and Conduction Disorders
por: Mustafa, Saim, et al.
Publicado: (2023)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)
por: Lau, Kolja, et al.
Publicado: (2022)

Persistent increase in cardiac troponin I in Fabry disease: a case report
por: Tanislav, Christian, et al.
Publicado: (2011)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

A Case of Fabry Cardiomyopathy
por: Nah, Jong Chun, et al.
Publicado: (2009)

Impact of Regional Left Ventricular Function on Outcome for Patients with AL Amyloidosis
por: Liu, Dan, et al.
Publicado: (2013)

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019)

Value of low-dose dobutamine stress echocardiography on defining true severe low gradient aortic stenosis in patients with preserved left ventricular ejection fraction
por: Liu, Dan, et al.
Publicado: (2018)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0c4980ratp75ao9i5ndkv9sa2s